HOME - ROMANIAN
Sunday, December 17, 2017   00:28 EET
 

 

 

 

 

Implementation of a complex genome profiling diagnostic algorithm for patients with congenital and developmental abnormalities (CONGEN)

Short presentation of the Partners

CO is one of Romania’s leading centers in basic and applied biomedical research. CO has multiple completed or ongoing internationally funded projects (NIH, FP7, bilateral projects) and also national projects in molecular genetics, genetic epidemiology, oncology, virology, and molecular biology that allowed the set-up of a state of the art infrastructure at international standards. Also, these projects contributed to form a team of highly trained specialists in molecular genetics, oncobiology and drug testing in malignant processes. Coordinating organization will be involved in extraction, analysis, QA and QC procedures, inclusion of extracted DNA/RNA in a sample bank, participates in building the database and will perform part of molecular genetic analysis (PCR, MS-MLPA, sequencing). Our expertise in setting-up sample banks according to international standards and proficiency in molecular genetics new investigation methods, is supported by Thomson Reuter papers published in this field, certify the good development of the project, assuring high feasibility and the achievement of the proposed goals.

 

P1 is an important medical and research institution in Romania, offering: multidisciplinary health care services, excellent research for mother and child, promoting health for population, undergraduate and postgraduated medical education and coordination of National Programs of Ministry of Health. It is the only public hospital in Bucharest including a clinical genetics department associated to a cytogenetic laboratory, which is participating to Cytogenetic European Quality Assessment (CEQA) since 2009 for postnatal diagnosis. In this project P1 will be involved in the selection of the patients, cytogenetic activities (conventional cytogenetic techniques and FISH testing) and genetic counseling and the results of this project will help improving the diagnosis of congenital disorders and genetic counseling implementing the algorithm that will result from this project in a major public medical care unit in Bucharest area.

 

P2 is one of the oldest medical schools in Romania with distinguished tradition in teaching, research and health service; P2 is a university ranked among those performing Advanced Research and Education, and is accredited as an institution of research and development. Scientific research activity is the central component of the academic mission of providing an adequate formative educational process for undergraduate degree programs, Masters and PhD. In the 2006-2011, UMFIS won an FP7 project as coordinator, is a partner in two FP7 projects, was a partner in an FP6 project, was conducted for a total of nine applied research contracts from PN II. UMFIS has a good infrastructure for research, one of the best laboratories being the Central Immunology and Genetics Laboratory, that had been the result of implementation of Interdisciplinary Platform for Molecular Medicine (platform CNCSIS - grant 29/2006 (contract No. 32/06.06.2006), contract value: 3.78 million RON). The medical genetics department of P2 is one of the best in Romania, with a high well-trained number of specialists and with a good experience in clinical genetics and cytogenetic or molecular activity. In this project P2 will be involved in the selection of the patients, cytogenetic activities (conventional cytogenetic techniques and FISH testing) and genetic counseling in Moldova region and the results of this project will help improving the diagnosis of congenital disorders and genetic counseling, implementing the algorithm that will result from this project in a major public genetic laboratory in Moldova Region.

 

 

P3 is a private health care and diagnostics company that focuses on two business areas:  diagnostic services and research & innovation. P3 will be involved in providing gene testing through array-CGH technique, Next generation sequencing, bio-statistical analyzing and interpretation of the results, integration of the results in a sample bank, and participating in building the data base. PG has state of art equipment for performing tests in order to discover new rare disease, such as next generation sequencing, and will apply the expertise of trained personnel in the aCGH and next generation sequencing in order develop better diagnostic and genetic counseling services. Most importantly, Personal Genetics Ltd. will use the integrated results of the project for better recurrence risk counseling and clinical management of the patients via extending its portfolio with most relevant molecular services that will be competitive with the ones offered by clinics in well developed countries. The company has a well established Marketing and Sales Department that will be able to disseminate the knowledge and advertise promptly the importance of the new services included in the new portfolio.

Return to main page of CONGEN

RO EN